Phosphorex

Hopkinton, MA
Polymer Nanoparticle (PNP) Lipid Nanoparticle (LNP) PLGA / PLA / PCL / PBAE / Cationic Polymer NPs mRNA LNP Small Molecule Nanoformulation
Program data pending ClinicalTrials.gov matching
60.0
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ✓ Press (9) ○ EMA GMP ○ MHRA GMP

Quick Facts: Phosphorex

Signal Score
60.0/100
Quality Compliance
Assessment pending
Headquarters
Hopkinton, MA
Modalities
Polymer Nanoparticle (PNP), Lipid Nanoparticle (LNP), PLGA / PLA / PCL / PBAE / Cationic Polymer NPs, mRNA LNP, Small Molecule Nanoformulation
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Phosphorex

Auto-created by AI matchmaker. Data verification pending.

Signal Score & Pillar Breakdown

Quality Compliance
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs no verified data
Sponsorsno verified data
ModalitiesPolymer Nanoparticle (PNP), Lipid Nanoparticle (LNP), PLGA / PLA / PCL / PBAE / Cationic Polymer NPs, mRNA LNP, Small Molecule Nanoformulation
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: SEC EDGAR, press monitoring
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 60.0
Broad modality coverage (5 modalities)
Source: SEC EDGAR, press monitoring, company profiles
Profile-based capacity assessment
Recent Press9 articles
Broad modality coverage (5 modalities)

Recent News 9 articles

news Wed, 24 Ju
Phosphorex to Host a Virtual Panel Discussion Exploring Targeted Lipid Nanoparticle Development for Extrahepatic Delivery - PR Newswire
news Wed, 13 Au
Phosphorex, NOF Corporation, NeoSome Life Sciences, NIS, and Envol Biomedical Form the LNP Alliance - Contract Pharma
news Wed, 13 Au
Phosphorex Appoints Jerry Williamson as Chief Executive Officer - PR Newswire
news Tue, 30 Ap
Phosphorex and NOF CORPORATION Collaborate to Supply Lipid Nanoparticle Formulations using NOF's Proprietary Ionizable Lipid, COATSOME® SS Series - PR Newswire
news Tue, 25 Fe
MassBio Member Spotlight: Phosphorex - Massachusetts Biotechnology Council
news Tue, 09 Ju
Phosphorex Appoints John Rigg to Board of Directors - PR Newswire
news Tue, 02 Ju
Phosphorex Names John Rigg Chairman of the Board - PR Newswire
news Thu, 17 Au
Biopharmaceutical Mergers and Acquisitions: Their Impact on the Services Industry - BioProcess International
news Fri, 09 Au
Phosphorex Welcomes NOF CORPORATION as Shareholder and Strategic Partner - PR Newswire

Frequently Asked Questions About Phosphorex

What is Phosphorex's CDMO Signal Score?
Phosphorex has a Signal Score of 60/100, based on quality, operations, financial stability, and capacity data.
Evaluating Phosphorex for a manufacturing program?
Use the free AI matchmaker to compare Phosphorex against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Lipid Nanoparticle (LNP) CDMOs → mRNA LNP CDMOs →